#1 Clinical Trials Search in Europe

Clinical Trials By Country

Explore medical research studies available worldwide

Austria

1000+ Trials
100+ centers
Latest trial:
A study to evaluate the efficacy and safety of obinutuzumab compared to prednisolone in adults with newly onset minimal change disease

Belgium

2000+ Trials
200+ centers
Latest trial:
Study of PF-08653945 Bioavailability After Subcutaneous Injection in the Thigh, Upper Arm, or Abdomen in Adults with Obesity

Bulgaria

700+ Trials
400+ centers
Latest trial:
Study of TYRA-300 in Adults with Low Grade Upper Tract Urothelial Carcinoma to Assess Efficacy and Safety

Croatia

200+ Trials
61 centers
Latest trial:
Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Cyprus

16 Trials
5 centers
Latest trial:
Efficacy and tolerability of diclofenac potassium + thiocolchicoside versus diclofenac potassium in patients with acute severe low back pain

Czechia

1400+ Trials
600+ centers
Latest trial:
Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Denmark

1400+ Trials
100+ centers
Latest trial:
A study on azithromycin for preventing airway infections in children aged 0-72 months with structural lung damage or congenital lung and airway malformations

Estonia

100+ Trials
45 centers
Latest trial:
Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Finland

500+ Trials
100+ centers
Latest trial:
Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

France

3900+ Trials
900+ centers
Latest trial:
A study to evaluate the efficacy and safety of obinutuzumab compared to prednisolone in adults with newly onset minimal change disease

Germany

3400+ Trials
2000+ centers
Latest trial:
A study to evaluate the efficacy and safety of obinutuzumab compared to prednisolone in adults with newly onset minimal change disease

Greece

1000+ Trials
100+ centers
Latest trial:
Metronidazole, Bismuth Oxide and Tetracycline Hydrochloride Fixed‑Dose Combination vs Standard First‑line Therapy for Adults with Helicobacter pylori Infection

Guadeloupe

2 Trials
1 centers
Latest trial:
Comparing the timing of etoposide and dexamethasone treatment for patients with severe sporadic hemophagocytic lymphohistiocytosis in intensive care.

Hungary

1200+ Trials
300+ centers
Latest trial:
A study to evaluate the safety and how pivekimab sunirine works in children with relapsed or refractory acute myeloid leukemia

Iceland

29 Trials
2 centers
Latest trial:
Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

India

0 Trials
1 centers

Ireland

400+ Trials
43 centers
Latest trial:
Long-term safety and effectiveness study of CYB003 (deupsilocin besilate) with optional additional doses for people with Major Depressive Disorder

Israel

0 Trials
1 centers

Italy

3400+ Trials
500+ centers
Latest trial:
Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Latvia

100+ Trials
78 centers
Latest trial:
Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Lithuania

200+ Trials
78 centers
Latest trial:
Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Luxembourg

33 Trials
4 centers
Latest trial:
Comparing AZD5335 with Mirvetuximab Soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Norfolk Island

0 Trials
1 centers

Norway

600+ Trials
100+ centers
Latest trial:
Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Poland

2500+ Trials
1500+ centers
Latest trial:
Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Portugal

700+ Trials
76 centers
Latest trial:
Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Réunion

2 Trials
6 centers
Latest trial:
Study on the Effectiveness and Safety of Chikungunya Vaccine (VLA-1553) for People at Risk of Severe Chikungunya in La Réunion

Romania

700+ Trials
400+ centers
Latest trial:
QTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia

Slovakia

400+ Trials
300+ centers
Latest trial:
Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Slovenia

98 Trials
27 centers
Latest trial:
RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

Spain

4200+ Trials
400+ centers
Latest trial:
Study of IDP-121 with chemotherapy for patients with relapsed small cell lung cancer

Sweden

900+ Trials
100+ centers
Latest trial:
Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

The Netherlands

2200+ Trials
200+ centers
Latest trial:
Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

United Kingdom

2 Trials
1 centers
Latest trial:
Study of Atropine Sulfate eye drops (0.

United States

2 Trials
1 centers
Latest trial:
A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease